Zepp Health (ZEPP) Q4 2025 Earnings Transcript

Zepp Health reported Q4 revenue of $85.2 million, up 43% year over year, with full-year revenue rising 41.8% to $259 million and Q4 gross margin reaching a record 40.4%. Adjusted net loss narrowed sharply to $6.4 million in Q4 from $22.5 million a year ago, while cash increased to $113 million and inventory declined to $72.8 million. Management guided Q1 2026 revenue to $50 million-$55 million, cited continued premium product launches and share buybacks, and said higher costs were largely non-structural.

Analysis

The market is likely underestimating how much of the margin inflection is mix-driven rather than demand-driven. That matters because mix expansion is stickier than promotional leverage: once the high-end portfolio resets ASPs and consumer expectations, gross margin can hold even if unit growth normalizes. The more important second-order effect is competitive, as Zepp is moving out of the “good enough cheap wearable” bucket and into a category where brand, software, and athlete credibility matter more than spec-sheet parity.

The operating leverage story is also more durable than the headline expense spike suggests. A meaningful share of the Q4 cost build was timing-related and should reverse as launch cadence normalizes, which creates a cleaner 2026 earnings inflection than the current P&L implies. The real watch item is whether the company can sustain premium sell-through without resorting to discounting if consumer electronics demand softens; if they can, the business becomes less cyclical and deserves a higher multiple.

The biggest non-obvious risk is supply, not demand. The Helio Strap bottleneck implies management is still underestimating demand at the premium/performance end, which is good for long-term brand but bad if inventory allocation forces lost share in the next two quarters. Also, the balance-sheet/buyback narrative only works if working capital stays tight; any re-acceleration in inventory or component pre-buys would quickly absorb cash and make repurchases look cosmetic rather than accretive.

Key Decisions for Investors

• Go long ZEPP on pullbacks over the next 1-2 weeks, using the Q1 guide as a near-term catalyst; risk/reward is attractive if the market values the 2026 margin reset, but trim if the stock re-rates ahead of evidence on sustained premium sell-through.
• Pair trade: long ZEPP / short a lower-quality consumer hardware peer with weaker brand and worse gross margin durability for 1-3 months; the relative winner should be the name with genuine ASP expansion and less promotional dependence.
• Buy ZEPP calls or a call spread into the next earnings window if implied volatility remains modest; this is a cleaner expression of the 1H26 operating leverage inflection, with upside tied to margin continuation rather than just revenue growth.
• Avoid shorting ZEPP outright unless inventory or channel checks show discounting returning; the current setup has too much self-help and too little balance-sheet distress for a clean short.
• Set a tactical exit if inventory turns back up for two consecutive quarters or if Q2 guidance fails to confirm normalizing opex; those would be the first signs the premium thesis is stalling.